Common and Contrasting Characteristics of the Chronic Soft-Tissue Pain Conditions Fibromyalgia and Lipedema

Felix Angst, Thomas Benz, Susanne Lehmann, Peter Sandor, Stephan Wagner, Felix Angst, Thomas Benz, Susanne Lehmann, Peter Sandor, Stephan Wagner

Abstract

Objective: To examine the common and specific characteristics of fibromyalgia and lipedema, two chronic soft-tissue pain syndromes without curative therapy options.

Methods: Diseases' characteristics were compared using the findings of extensive literature and the empiric data from two cohorts, both fulfilling standardized diagnostic criteria. Outcome was measured by various socio-demographics, the generic Short Form 36 (SF-36), the Fibromyalgia Severity Questionnaire (FSQ), and the 6-minute walk distance (6MWD). Empiric SF-36 data were compared to specific population-based norms and between the diagnostic groups, using standardized mean differences (SMD).

Results: Female participants with fibromyalgia (n = 77) and lipedema (n = 112) showed comparable education levels and living situations. Lipedema cases were, on average, 3.9 years younger and BMI 6.3kg/m2 more obese. Women with fibromyalgia smoked more, did less sport, had more comorbidities, and worked less. Compared to the norms, health in fibromyalgia was worse than expected by SMD = -1.60 to -2.35 and in lipedema by -0.44 to -0.82 on the SF-36. The score differences between the two conditions ranged from SMD = -0.96 to -1.34 (all p < 0.001) on the SF-36 and the FSQ. For the inpatients (n = 77 fibromyalgia, n = 38 lipedema), the 6MWD was comparable (SMD = -0.09, p = 0.640). These findings were consistent with detailed data from the literature reviewed.

Discussion: Fibromyalgia and lipedema share characteristics of clinical phenomenology and comorbid conditions. Disease perception is more pronounced in fibromyalgia than in lipedema, especially in social and role dysfunction, whereas the walking distance was similar for both syndromes. This difference may be explicable by limited coping skills in fibromyalgia.

Keywords: SF-36; diagnosis; fibromyalgia; lipedema; outcome measures.

Conflict of interest statement

Dr Stephan Wagner reports personal fees from Essity Switzerland, personal fees from Sigvaris Switzerland, personal fees from Berro Switzerland/Juzo Germany, outside the submitted work. There are no conflicts of interests or competing interests to declare.

© 2021 Angst et al.

References

    1. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Lond Engl. 2017;390(10100):1260–1344. doi:10.1016/S0140-6736(17)32130-X.
    1. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):356. doi:10.1007/s11916-013-0356-5
    1. Shavit E, Wollina U, Alavi A. Lipoedema is not lymphoedema: a review of current literature. Int Wound J. 2018;15(6):921–928. doi:10.1111/iwj.12949
    1. Reich-Schupke S, Schmeller W, Brauer WJ, et al. S1 guidelines: lipedema. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2017;15(7):758–767. doi:10.1111/ddg.13036
    1. Angst F, Verra M, Lehmann S, Brioschi R, Aeschlimann A. Clinical effectiveness of an interdisciplinary pain management programme compared with standard inpatient rehabilitation in chronic pain: a naturalistic, prospective controlled cohort study. J Rehabil Med. 2009;41(7):569–575. doi:10.2340/16501977-0381
    1. Gota CE, Kaouk S, Wilke WS. Fibromyalgia and obesity: the association between body mass index and disability, depression, history of abuse, medications, and comorbidities. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2015;21(6):289–295. doi:10.1097/RHU.0000000000000278
    1. Gensior MHL, Cornely M. [Pain in lipoedema, fat in lipoedema and its consequences: results of a patient survey based on a pain questionnaire]. Handchir Mikrochir Plast Chir. 2019;51(4):249–254. doi:10.1055/a-0942-9607. German
    1. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53(4):519–527. doi:10.1002/art.21319
    1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990;33(2):160–172. doi:10.1002/art.1780330203
    1. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600–610. doi:10.1002/acr.20140
    1. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–329. doi:10.1016/j.semarthrit.2016.08.012
    1. Halk AB, Damstra RJ. First Dutch guidelines on lipedema using the international classification of functioning, disability and health. Phlebology. 2017;32(3):152–159. doi:10.1177/0268355516639421
    1. Wollina U, Heinig B. Differential diagnostics of lipedema and lymphedema: a practical guideline. Z Rheumatol. 2018;77(9):799–807. doi:10.1007/s00393-018-0546-y
    1. Angst F, Lehmann S, Aeschlimann A, Sandòr PS, Wagner S. Cross-sectional validity and specificity of comprehensive measurement in lymphedema and lipedema of the lower extremity: a comparison of five outcome instruments. Health Qual Life Outcomes. 2020;18(1):245. doi:10.1186/s12955-020-01488-9
    1. Angst F, Brioschi R, Main CJ, Lehmann S, Aeschlimann A. Interdisciplinary rehabilitation in fibromyalgia and chronic back pain: a prospective outcome study. J Pain. 2006;7(11):807–815. doi:10.1016/j.jpain.2006.03.009
    1. Dutch Society for Dermatology and Venereology (NDVD). Dutch lipoedema guideline; 2014. Available from:. Accessed July6, 2021.
    1. Wounds UK. Best Practice Guidelines: The Management of Lipoedema. London: Wounds UK, 2017. Available from: . Accessed August 31, 2021.
    1. Angst F, Aeschlimann A, Steiner W, Stucki G. Responsiveness of the WOMAC osteoarthritis index as compared with the SF-36 in patients with osteoarthritis of the legs undergoing a comprehensive rehabilitation intervention. Ann Rheum Dis. 2001;60(9):834–840.
    1. Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health-related quality of life: medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res. 2011;63 Suppl 11:S383–S412. doi:10.1002/acr.20541
    1. Bullinger M, Kirchberger I. Fragebogen zum Gesundheitszustand: SF-36; Handanweisung [The SF-36 questionnaire to assess health status. A manual]. Hogrefe: Verlag für Psychologie; 1998.
    1. Ware JE, Snow KK, Kosinski M, Gandek B; New England Medical Center Hospital, Health Institute. SF-36 Health Survey: Manual and Interpretation Guide. 3rd ed. Health Institute, New England Medical Center; 2004
    1. Kurth B-M, Ellert U. The SF-36 questionnaire and its usefulness in population studies: results of the German health interview and examination survey 1998. Soz Praventivmed. 2002;47(4):266–277. doi:10.1007/BF01326408
    1. Bennell K, Dobson F, Hinman R. Measures of physical performance assessments: self-Paced Walk Test (SPWT), Stair Climb Test (SCT), Six-Minute Walk Test (6MWT), Chair Stand Test (CST), Timed Up & Go (TUG), Sock Test, Lift and Carry Test (LCT), and Car Task. Arthritis Care Res. 2011;63 Suppl 11:S350–S370. doi:10.1002/acr.20538
    1. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J Clin Res Ed. 1982;284(6329):1607–1608. doi:10.1136/bmj.284.6329.1607
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117. doi:10.1164/ajrccm.166.1.at1102.
    1. Borenstein M. Effect sizes for continuous data. In: The Handbook of Research Synthesis and Meta-Analysis. 2nd ed. Russell Sage Foundation; 2009:221–235.
    1. Angst F, Aeschlimann A, Angst J. The minimal clinically important difference raised the significance of outcome effects above the statistical level, with methodological implications for future studies. J Clin Epidemiol. 2017;82:128–136. doi:10.1016/j.jclinepi.2016.11.016
    1. Häuser W, Ablin J, Fitzcharles M-A, et al. Fibromyalgia. Nat Rev Dis Primer. 2015;1:15022. doi:10.1038/nrdp.2015.22
    1. Okhovat J-P, Alavi A. Lipedema: a review of the literature. Int J Low Extrem Wounds. 2015;14(3):262–267. doi:10.1177/1534734614554284
    1. Bauer A-T, von Lukowicz D, Lossagk K, et al. New insights on lipedema: the enigmatic disease of the peripheral fat. Plast Reconstr Surg. 2019;144(6):1475–1484. doi:10.1097/PRS.0000000000006280
    1. Skaer TL, Kwong WJ. Illness perceptions and burden of disease in fibromyalgia. Expert Rev Pharmacoecon Outcomes Res. 2017;17(1):9–15. doi:10.1080/14737167.2017.1270207
    1. Fitzcharles M-A, Perrot S, Häuser W. Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain Lond Engl. 2018;22(9):1565–1576. doi:10.1002/ejp.1252
    1. Salaffi F, Di Carlo M, Carotti M, Farah S, Ciapetti A, Gutierrez M. The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values. Acta Bio-Medica. 2019;89(4):541–557. doi:10.23750/abm.v89i4.7298
    1. Angst F, Benz T, Lehmann S, et al. Extended overview of the longitudinal pain-depression association: a comparison of six cohorts treated for specific chronic pain conditions. J Affect Disord. 2020;273:508–516. doi:10.1016/j.jad.2020.05.044
    1. Clay FJ, Fitzharris M, Kerr E, McClure RJ, Watson WL. The association of social functioning, social relationships and the receipt of compensation with time to return to work following unintentional injuries to Victorian workers. J Occup Rehabil. 2012;22(3):363–375. doi:10.1007/s10926-012-9354-4
    1. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2008;62(1):115–126. doi:10.1111/j.1742-1241.2007.01638.x
    1. Estévez-López F, Álvarez-gallardo IC, Segura-Jiménez V, et al. The discordance between subjectively and objectively measured physical function in women with fibromyalgia: association with catastrophizing and self-efficacy cognitions. The al-Ándalus project. Disabil Rehabil. 2018;40(3):329–337. doi:10.1080/09638288.2016.1258737
    1. Häuser W, Fitzcharles M-A. Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci. 2018;20(1):53–62.
    1. Dudek JE, Białaszek W, Ostaszewski P. Quality of life in women with lipoedema: a contextual behavioral approach. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2016;25(2):401–408. doi:10.1007/s11136-015-1080-x

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する